Morgan Stanley’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Morgan Stanley’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-101	Closed	–	–	6906
2019 Q3	$0	Sell	101 -734,377	-100%	-$497K	﹤0.01%	6886
2019 Q2	$639K	Sell	734,478 -134,049	-15%	-$210K	﹤0.01%	4475
2019 Q1	$2.02M	Buy	868,527 +169,798	+24%	+$460K	﹤0.01%	3572
2018 Q4	$1.62M	Buy	698,729 +154,300	+28%	+$1.36M	﹤0.01%	3936
2018 Q3	$8.07M	Buy	544,429 +153,014	+39%	+$2.43M	﹤0.01%	2646
2018 Q2	$5.95M	Buy	391,415 +107,239	+38%	+$1.82M	﹤0.01%	2952
2018 Q1	$5.34M	Buy	284,176 +156,614	+123%	+$2.74M	﹤0.01%	2966
2017 Q4	$2.32M	Buy	127,562 +66,050	+107%	+$1.4M	﹤0.01%	3909
2017 Q3	$1.37M	Buy	+61,512	New	+$1.35M	﹤0.01%	4210

Other funds holding SNNA

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Private Ocean San Rafael, California $1.13B AUM 11.01% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Morgan Stanley's SNNA Position: Q4 2019 in Review

Morgan Stanley sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q4 2019, closing a stake of 101 shares.

Morgan Stanley first reported a position in SNNA in Q3 2017 and held it in 9 quarters. The position peaked at $8.07M in Q3 2018. 4 funds tracked by Wall St. Rank hold SNNA as of Q4 2019.

Morgan Stanley reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
Morgan Stanley sold 101 Sienna Biopharmaceuticals, Inc. shares in Q4 2019.
Morgan Stanley first reported a position in Sienna Biopharmaceuticals, Inc. in Q3 2017 and held it in 9 quarters.
Morgan Stanley's Sienna Biopharmaceuticals, Inc. position peaked at $8.07M in Q3 2018.
4 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q4 2019.

Based on Morgan Stanley's 13F filing for Q4 2019, filed 14 Feb 2020.